Tilray turns first medical cannabis provider in Portugal
The license makes the company the first of its kind in the Southern European country.

Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that it has received the necessary approvals and marketing authorization under Portuguese law to sell Tilray medical cannabis products in Portugal from its GMP certified EU facility in Cantanhede, Portugal. Marketing authorization was granted by Infarmed, the Portuguese national drug and health product agency, whose rigorous process for obtaining such authorization is internationally recognized. This is the first time a full quality dossier has been required and delivered in order to obtain marketing authorization in Europe for a medical cannabis product and the process is now complete. Infarmed's approval confirms the quality and safety standards of Tilray's Good Manufacturing Processes (GMP) certified production. According to Infarmed and the Portuguese Medical Cannabis Regulations, Tilray's medical cannabis products are approved for the treatment of spasticity related to multiple sclerosis or spinal cord injury, nausea and vomiting (as a result of chemotherapy, radiation therapy and combined HIV medication for hepatitis C); Appetite stimulation in palliative care for patients undergoing oncological treatment or suffering from HIV / AIDS; Tourette Syndrome, Epilepsy, and Treatment of Severe Seizure Disorders in Children; Therapy-resistant glaucoma and chronic pain (in connection with oncological diseases or diseases of the nervous system, such as neuropathic pain conditions due to nerve damage, phantom pain, trigeminal neuralgia or after herpes zoster). Brendan Kennedy, Tilray Chief Executive Officer, said, "Tilray is committed to quality and patient safety and we look forward to significantly improving the quality of life for Portuguese patients through our medicinal cannabis products." Sascha Mielcarek, Tilray's Managing Director in Europe, says: "We are very proud of Infarmed's marketing approval, which confirms that Tilray's medical cannabis products meet the highest national and international quality standards." He continued: "Patient demand is growing in Portugal and across Europe and our aim is to bring them the safest, highest quality medicinal cannabis products available. Patients can purchase Tilray products through major pharmaceutical distribution channels in Portugal and other European markets We are confident that as demand increases around the world and more medical cannabis markets (regulated or licensed) emerge, Tilray's EU campus will be ready to serve more partners and patients in the EU and other international medical markets. " In May 2020, Tilray received the third and full Good Manufacturing Practice (GMP) certification for Tilray Portugal. The full GMP certification allows Tilray to manufacture medicinal cannabis extracts in-house and to export GMP-produced medical cannabis finished products, both dried flower and oil, from Portugal to the entire European Union and other international markets with approved national medical cannabis programs. The certification also authorizes Tilray to manufacture bulk extracts on-site for sale as cannabis APIs (Active Pharmaceutical Ingredients), and provides additional laboratory quality control capabilities to further advance product innovation and research capabilities.

